Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season - 14/02/22
, Naoki Kawai b, Yong Chong a, Takuma Bando b, Norio Iwaki b, Seizaburo Kashiwagi b, Hideyuki Ikematsu b, cSummary |
Objectives |
To investigate the susceptibility of epidemic influenza viruses to neuraminidase inhibitors (NAIs) and the emergence of resistant viruses after treatment, a prospective, observational study was done in the 2019-20 Japanese influenza season.
Methods |
Influenza viruses were isolated before and twice after treatment, the first at day 5 and the second at day 10. The 50% inhibitory concentrations (IC50s) to oseltamivir, zanamivir, peramivir, and laninamivir were measured and compared with those of 2010-11 to 2018-19 seasons. NA amino acid sequences were analyzed by next generation sequencing (NGS).
Results |
The IC50 geometric means of the NAIs for 128 A(H1N1)pdm09, 2 A(H3N2), and 33 B were comparable to those of the previous seasons. Only 2 (1.6%) A(H1N1)pdm09 with significantly high IC50 to oseltamivir were found pretreatment. No A(H3N2) or B had resistance. Treatment-emergent oseltamivir resistance was found in 2 among 33 oseltamivir-treated A(H1N1)pdm09, only at the second follow-up. The NGS indicated a rapid increase in the proportion of H275Y to wild type, from 0% to almost 100% between days 5 and 10.
Conclusions |
These results suggest the continued effectiveness of these NAIs for epidemic influenza in Japan. Treatment-emergent resistant H275Y A(H1N1)pdm09 viruses were detected after oseltamivir treatment, rapidly replacing the wild type.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Neuraminidase inhibitors (NAIs) susceptibility was maintained and no increase of resistant virus was found. |
• | Treatment-emergent resistance was found in A(H1N1)pdm09 treated with oseltamivir. |
• | H275Y mutants rapidly replaced the wild type after oseltamivir treatment. |
Keywords : Influenza virus, Neuraminidase inhibitor, Oseltamivir, Inhibitory concentration 50, Resistance
Plan
Vol 84 - N° 2
P. 151-157 - février 2022 Retour au numéro
Article précédent
- Burden of influenza disease in children under 2 years of age hospitalized between 2011 and 2020 in France
- Célia Tillard, Emmanuel Chazard, Karine Faure, Stéphanie Bartolo, Alain Martinot, François Dubos
- Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies
- S.A. Behnood, R. Shafran, S.D. Bennett, A.X.D. Zhang, L.L. O'Mahoney, T.J. Stephenson, S.N. Ladhani, B.L. De Stavola, R.M. Viner, O.V. Swann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?